15. Subsequent Events

On January 28, 2026, the company announced a common stock purchase agreement with Tumim Stone Capital, LLC.  Pursuant to the purchase agreement, the company has the right, but not the obligation, to sell to the investor up to $6 million subject to the limitations imposed by General Instruction I.B.6 of Form S-3.

On February 18, 2026, the company announced that the first patients have been dosed in a VA funded investigator-initiated Phase 2 trial evaluating Stenoparib for the treatment of relapsed small cell lung cancer.  The trial is being conducted in collaboration with the US Department of Veterans Affairs at 11 medical centers throughout the United States. 

In February 2026, the Allarity board approved a stock repurchase plan of up to $5 million over a 12 month period upon the term expiration of the prior repurchase plan on March 1, 2026.

On March 2, 2026, the company issued non-convertible promissory notes to Streeterville Capital for net proceeds of $20.0 million.